Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-01-12
2010-11-02
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S239100, C424S570000, C514S002600
Reexamination Certificate
active
07824694
ABSTRACT:
The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., abotulinumtoxin, where the methods comprise a “wash-down” (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions relates to methods for enhancing the therapeutic effects of a neurotoxin for treating pain, e.g., headache pain.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6503884 (2003-01-01), Ehrenberg et al.
patent: 6623742 (2003-09-01), Voet
patent: 6787517 (2004-09-01), Gil et al.
patent: 6838434 (2005-01-01), Voet
patent: 6869610 (2005-03-01), Aoki et al.
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0028706 (2004-02-01), Aoki et al.
patent: 2004/0213811 (2004-10-01), Ackerman
patent: 2005/0123567 (2005-06-01), First
patent: 2005/0147625 (2005-07-01), First
patent: 2005/0191320 (2005-09-01), Turkel et al.
patent: 2005/0191321 (2005-09-01), Turkel et al.
patent: 101 50 415 (2001-11-01), None
patent: WO 03/011333 (2002-07-01), None
Silberstein et al., Headache 40: 445-450, 2000.
Schulte-Mattler et al., Eur J Neurol. 13 Suppl 1:51-54, 2006.
Schim., Curr Med Res and Opin 20: 49-53, 2004.
Blumenfeld, Headache 42: 420, Abstract F20, 2002.
Setler. Clin J Pain 18: S119-S124, 2002.
Aurora, Exp Opin Pharmacother 7:1085-1095, 2006.
Goadsby Exp Opin Emerging Drugs 11(3): 419-427, 2006.
Elkind et al. J Pain 7: 688-696, 2006.
Ferrante et al., Anesthesiology 103: 377-83, 2005.
Shulte-Mattler et al. J Neurol Trans 115: 647-651, 2008.
Jankovic J Neurol Neurosurg Psych 75: 951-957, 2004.
Schulte-Mattler et al. Drug Dev Res 68: 397-402, 2007.
U.S. Appl. No. 60/418,789, filed Oct. 15, 2002, Katz.
Aoki K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia Sep. 2003;23(7), p. 649.
Aoki, K., et al.,Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions, Eur J. Neurol 2001: (suppl 5), pp. 21-29.
Aoki, K.,Physiology and pharmacology of therapeutic botulinum neurotoxins, in Kreyden, O., editor, Hyperhidrosis and botulinum toxin in dermatology, Basel, Karger; 2002; 30, pp. 107-116.
Bhattacharya K., et al.,Novel uses of botulinum toxin type A: two case reports, Mov Disord 2000; 15(Suppl 2), pp. 51-52.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research, 1985, 360, pp. 318-324.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol, 1981, 316, pp. 244-251.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry; 1990 265(16), pp. 9153-9158.
Blugerman G., et al.,Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg May 2003;29(5), pp. 557-559.
Borodic, et al., Eds. Jankovic J. et al., Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 150.
Boyd,Mov Disord,1995, 10(3):376.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas, Lancet, 1995, 345, pp. 1008-1012.
Brin, M., et al.,Botulinum toxin type A: pharmacology, in Mayer N., editor, Spasticity: etiology, evaluation, management and the role of botulinum toxin, 2002; pp. 110-124.
Bushara K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3), p. 507.
Coffield et al., Eds. Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), Chapter 1.
Cui, M., et al.,Mechanisms of the antinociceptive effect of subcutaneous BOTOX® : inhibition of peripheral and central nociceptive processing, Naunyn Schmiedebergs Arch Pharmacol 2002; 365 (supp 2): R17.
Dabrowski, et al,Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome, Ann Neurol Sep. 2002;52(3 Supp 1):S157.
Durham PL, Cady R, Blumenfled AJ.Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache; 2004, pp. 35-43.
Fung L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58:1998; pp. 672-684.
Gonelle-Gispert, et al.,Biochem J, 1999, 1;339 (pt 1), pp. 159-165.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2):1988; pp. 522-527.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H ]Noradrenaline and [3H ]GABA From Rat Brain HomogenateExperientia 44:1988; pp. 224-226.
Habermann,Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, pp. 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14thedition, published by McGraw Hill.
Heckmann M., et al.,Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol Apr. 2002;46(4), pp. 617-9.
Jahanshahi M., et al.,Psychological functioning before and after treatment of torticollis with botulinum toxin, J Neurol Neurosurg Psychiatry 1992; 55(3), pp. 229-231.
Jost W.,Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis Sep. 2002;17(5), pp. 298-302.
Katsambas A., et al.,Cutaneous diseases of the foot: Unapproved treatments, Clin Dermatol Nov.-Dec. 2002;20(6), pp. 689-699.
Li Y, et al.,Sensory and motor denervation influences epidermal thickness in rat foot glabrous skin, Exp Neurol 1997;147, pp. 452-462.
Marjama-Lyons, J., et al.,Tremor-Predominant Parkinson's Disease, Drugs & Aging 16(4):2000, pp. 273-278.
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, Chapter 6 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Murry T., et al.,Spasmodic dysphonia; emotional status and botulinum toxin treatment, Arch Otolaryngol Mar. 1994; 120(3), pp. 310-316.
Naumann, Markus, et al.,Botulinum Toxin Type A in the Treatment of Focal, Axillary and Palmar Hyperhidrosis and Other Hyperhidrotic Conditions, European J. Neurology 6 (Supp 4):1999, pp. S111-S115.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9); pp. 1373-1412, (1997).
Ragona,The Laryngoscope109:1999, pp. 1344-1346.
Rogers J., et al.,Injections of botulinum toxin A in foot dystonia, Neurology Apr. 1993;43(4 Suppl 2).
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165:1987, pp. 675-681.
Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56, pp. 80-99.
Sevim, S., et al.,Botulinum toxin-A therapy for palmar and plantar hyperhidrosis, Acta Neurol Belg Dec. 2002;102(4), pp. 167-170.
Sharma Sahshi K, Singh BR.Enhancement of the endopepdidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry: 2004, pp.
First Eric R.
Irvine Ryan A.
Abel Kenton
Allergan Inc.
Condino Debra
Dutt Aditi
Nassif Claude L.
LandOfFree
Methods for enhancing therapeutic effects of a neurotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for enhancing therapeutic effects of a neurotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for enhancing therapeutic effects of a neurotoxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252290